HumanITCare Plans to Make the Commercial Leap to the US in 2024

HumanITCare, a Spanish company specialized in remote patient telemonitoring, hopes to land in the United States in 2024, said Núria Pastor, co-founder and CEO of HumanITcare.

To achieve the goal of reaching the United States, the Barcelona company has begun working with companies in the country and hopes to materialize its presence in North American territory in the coming months. At the moment, no further details have been released.

One of the latest projects HumanITCare has worked on and continues to work on is Tique, a European-wide initiative focused on providing rapid responses to complex patients suffering from advanced heart failure. The project in question is funded by the European research and development program Horizon2020 and the budget is more than four million euros.

Read more about HumanITCare and find the most important business news of the day with the Born2Invest mobile app.

HumanITCare leads the project on a technological and service delivery scale together with other companies such as Izertis, Sferanet and Additum Blockchain

Tique aims to develop a comprehensive service to facilitate a fully integrated care pathway for patients suffering from advanced heart failure, supported by advanced technologies and focused on patient needs. The goal is to facilitate the delivery of appropriate care, when and where needed.

Specifically, HumanITCare has the necessary tool and adapts its technology to transform the care path for patients with advanced heart failure, type 2 heart failure.

The company leads the project on a technological and service provision scale together with other companies such as Izertis, Sferanet and Additum Blockchain, according to the co-founder of the Spanish company.

The Barcelona company has sealed a three-year agreement with Clínicas Mi

HumanITcare is a technology company in the telemedicine sector. Through its medical software solution   , it allows hospitals, insurers and clinics to have a tool to remotely monitor  patients and anticipate possible relapses.

The HumanITcare system is made up of a medical portal that can be integrated into medical records  where the patients’ health is remotely viewed, and an  app, where patients track their vital signs, and can use the video calling or chat service.

In June 2023, the health company closed a collaboration agreement with Clínicas Mi to accompany cancer patients throughout their treatment, from any location, 24 hours a day, 365 days a year. The tool allows personalized monitoring, using artificial intelligence, facilitating comprehensive support from the professional and improving the patient’s quality of life.

The agreement, with an initial duration of three years, includes an exclusivity clause in oncology and Catalan territory according to which only Clínicas Mi centers will be able to offer this service for monitoring Cancer patients.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us